[1]李 卿,梁 斌.化疗栓塞联合替拉扎明治疗肝癌的研究进展[J].介入放射学杂志,2021,30(08):846-850.
 LI Qing,LIANG Bin..Research progress in the treatment of hepatocellular carcinoma with chemoembolization combined with tirapazamine[J].journal interventional radiology,2021,30(08):846-850.
点击复制

化疗栓塞联合替拉扎明治疗肝癌的研究进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年08
页码:
846-850
栏目:
综述
出版日期:
2021-08-25

文章信息/Info

Title:
Research progress in the treatment of hepatocellular carcinoma with chemoembolization combined with tirapazamine
作者:
李 卿 梁 斌
Author(s):
LI Qing LIANG Bin.
Department of Radiology, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Province 430022, China
关键词:
【关键词】 癌肝细胞 化疗栓塞治疗性 替拉扎明 缺氧
文献标志码:
A
摘要:
【摘要】 肝癌TACE后肿瘤复发率较高,这可能与栓塞后肿瘤缺氧及残存肿瘤细胞缺氧应答有关。替拉扎明是一种靶向缺氧细胞毒性药物,可以增强肿瘤放疗和化疗效果。TACE联合替拉扎明治疗肝癌有望达到协同抗肿瘤作用。本文就TACE治疗肝癌的原理与不足、替拉扎明靶向缺氧细胞毒性治疗机制及现状、TACE联合替拉扎明治疗肝癌的可行性及研究进展进行综述。

参考文献/References:

[1] Ming C, Hao W, Kai J, et al. TILA- TACE:an approach for effective local control of hepatocellular carcinoma[J]. J Intervent Med, 2018, 1: 58- 63.
[2] Gaba RC, Lokken RP, Hickey RM, et al. Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy[J]. J Vasc Interv Radiol, 2017, 28: 1210-1223.
[3] Phillips RM. Targeting the hypoxic fraction of tumours using hypoxia- activated prodrugs[J]. Cancer Chemother Pharmacol, 2016, 77: 441- 457.
[4] Marcu L, Olver I. Tirapazamine:from bench to clinical trials[J]. Curr Clin Pharmacol, 2006, 1: 71- 79.
[5] Titano J, Noor A, Kim E. Transarterial chemoembolization and radioembolization across Barcelona clinic liver cancer stages[J]. Semin Intervent Radiol, 2017, 34: 109- 115.
[6] Chen Y, Huang F, Deng L, et al. HIF- 1- miR- 219- SMC4 regulatory pathway promoting proliferation and migration of HCC under hypoxic condition[J]. Biomed Res Int, 2019, 2019: 8983704.
[7] Zhang X, Li Y, Ma Y, et al. Yes- associated protein(YAP) binds to HIF- 1α and sustains HIF- 1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress[J]. J Exp Clin Cancer Res, 2018, 37: 216.
[8] Liang B, Zheng CS, Feng GS, et al. Correlation of hypoxia- inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model[J]. Cardiovasc Intervent Radiol, 2010, 33: 806- 812.
[9] Gandara DR, Lara PN Jr, Goldberg Z, et al. Tirapazamine:prototype for a novel class of therapeutic agents targeting tumor hypoxia[J]. Semin Oncol, 2002, 29(1 Suppl 4): 102- 109.
[10] Moriwaki T, Okamoto S, Sasanuma H, et al. Cytotoxicity of tirapazamine(3- Amino- 1,2,4- benzotriazine- 1,4- dioxide)- induced DNA damage in chicken DT40 cells[J]. Chem Res Toxicol, 2017, 30: 699- 704.
[11] Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells[J]. Expert Opin Investig Drugs, 2009, 18: 77- 87.
[12] Reddy SB, Williamson SK. Tirapazamine:prototype for a novel class of therapeutic agents targeting tumor hypoxia[J]. Expert Opin Investig Drugs, 2009, 18: 77- 87.
[13] Siim BG, Menke DR, Dorie MJ, et al. Tirapazamine- induced cytotoxicity and DNA damage in transplanted tumors: relationship to tumor hypoxia[J]. Cancer Res, 1997, 57: 2922- 2928.
[14] Gatzemeier U, Rodriguez G, Treat J, et al. Tirapazamine- cisplatin: the synergy[J]. Br J Cancer, 1998, 77(Suppl 4):15- 17.
[15] 任 源,陈明辉,查 晓,等. TPZ联合LY294002对人宫颈癌细胞的体外抑制作用[J]. 华西药学杂志, 2008, 23:59- 60.
[16] 任 源,查 晓,张国楠. 替拉扎明联合磷脂酰肌醇- 3激酶抑制剂对人卵巢癌细胞的抑制作用[J]. 中华医学杂志, 2007, 87:1204- 1206.
[17] 杨伟志,Brown JM.生物还原剂SR4233对人脑胶质瘤细胞的细胞毒作用研究[J]. 中华放射肿瘤学杂志, 1999, 8:170- 172.
[18] Le QT, McCoy J, Williamson S, et al. Phase Ⅰ study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited- stage small cell lung cancer(s0004): a southwest oncology group study[J]. Cancer Res, 2004, 10: 5418- 5424.
[19] Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine,cisplatin,and radiotherapy in patients with advanced head and neck cancer[J]. J Clin Oncol, 2001, 19: 535- 542.
[20] Le QT, Moon J, Redman M, et al. Phase Ⅱ study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited- stage small- cell lung cancer: SWOG 0222[J]. J Clin Oncol, 2009, 27:3014- 3019.
[21] von Pawel J, von Roemeling R, Gatzemeier U, et al. Tirapazamine plus cisplatin versus cisplatin in advanced non- small- cell lung cancer: a report of the international CATAPULT Ⅰstudy group.Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non- Small- Cell Lung Tumors[J]. J Clin Oncol, 2000, 18: 1351- 1359.
[22] Rischin D, Narayan K, Oza AM, et al. Phase 1 study of tirapazamine in combination with radiation and weekly cisplatin in patients with locally advanced cervical cancer[J]. Int J Gynecol Cancer, 2010, 20: 827- 833.
[23] DiSilvestro PA, Ali S, Craighead PS, et al. Phase Ⅲ randomized trial of weekly cisplatin and irradiation versus cisplatin and tira- pazamine and irradiation in stages ⅠB2,ⅡA,ⅡB,ⅢB,and ⅣA cervical carcinoma limited to the pelvis: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2014, 32: 458- 464.
[24] Durand RE, Olive PL. Physiologic and cytotoxic effects of tirapazamine in tumor- bearing mice[J]. Radiat Oncol Investig, 1997, 5: 213- 219.
[25] Liang B, Xiong F, Wu H, et al. Effect of transcatheter intraarterial therapies on the distribution of doxorubicin in liver cancer in a rabbit model[J]. PLoS One, 2013, 8: e76388.
[26] Liapi E, Lee KH, Georgiades CC, et al. Drug- eluting particles for interventional pharmacology[J]. Tech Vasc Interv Radiol, 2007, 10: 261- 269.
[27] 翟 越,赵 卫,潘文秋,等. TACE联合载药微球治疗肝癌的研究进展[J]. 介入放射学杂志, 2019, 28:1211- 1214.
[28] Sonoda A, Nitta N, Ohta S, et al. Enhanced antitumor effect of tirapazamine delivered intraperitoneally to VX2 liver tumor- bearing rabbits subjected to transarterial hepatic embolization[J]. Cardiovasc Intervent Radiol, 2011, 34: 1272- 1277.
[29] Lin WH, Yeh SH, Yeh KH, et al. Hypoxia- activated cytotoxic agent tirapazamine enhances hepatic artery ligation- induced killing of liver tumor in HBx transgenic mice[J]. Proc Natl Acad Sci USA, 2016, 113: 11937- 11942.
[30] Abi- Jaoudeh N, Fernando D, Nelson K, et al. Phase Ⅰdose escalating study of hypoxia- activating agent tirapazamine in combination with trans- arterial emboliztion in patients with intermediate stage hepatocellular carcinoma[J]. J Hepatol, 2017, 66(1 Suppl): S456.
[31] Rischin D, Peters LJ,O’sullivan B,et al. Tirapazamine,cisplatin,and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck(TROG 02.02,HeadSTART): a phase Ⅲ trial of the Trans- Tasman Radiation Oncology Group[J]. J Clin Oncol, 2010, 28: 2989- 2995.

相似文献/References:

[1]申淑群,杨业发,葛乃建,等.肝癌破裂出血的介入与外科手术疗效评价[J].介入放射学杂志,2010,(07):544.
 SHEN Shuqun,YANG Yefa,GE Naijian,et al.Evaluation of interventional and surgical treatments for the hemorrhage of ruptured hepatocellular carcinoma[J].journal interventional radiology,2010,(08):544.
[2]郑加生,崔雄伟,禹纪红.自发性肝癌破裂出血的急诊动脉栓塞治疗[J].介入放射学杂志,2006,(04):228.
 ZHANG Jia-sheng,CUI Xiong-wei,YU Ji-hong,et al.Emergency transcatheter arterial embolization for beeding of hepatocellular carcinoma spontaneous rupture[J].journal interventional radiology,2006,(08):228.
[3]李强,曾从俊,王莺.化疗栓塞联合质子放射治疗肝癌合并门脉主干癌栓的临床应用[J].介入放射学杂志,2009,(04):278.
 LI Qiang,ZENG Congjun,WANG Ying.Interventional chemoembolization combined with proton radiotherapy for the treatment of hepatocellular carcinoma accompanied with portal cancerous thrombus[J].journal interventional radiology,2009,(08):278.
[4]张长青,吴伟岗,曾志雄,等.肝动脉化疗栓塞及注射~(32)P-胶体、无水乙醇综合序贯介入治疗原发性肝癌疗效分析[J].介入放射学杂志,2000,(01):22.
[5]经 翔,丁建民,王彦冬,等. 射频消融和微波消融治疗肝癌的比较[J].介入放射学杂志,2014,(04):306.
 JING Xiang,DING Jian? min,WANG Yan? dong,et al. Ultrasound-guided percutaneous radiofrequency ablation and microwave ablation for the treatment of hepatocellular carcinoma: a comparison study[J].journal interventional radiology,2014,(08):306.
[6]钱 晟,刘 嵘,王建华,等.栓塞肝动脉-门静脉瘘在TACE联合门静脉支架治疗肝癌伴门静脉癌栓中的临床意义[J].介入放射学杂志,2015,(04):306.
 QIAN Sheng,LIU Rong,WANG Jian hua,et al.Embolization of hepatic arterio portal shunt in patients with HCC complicated by portal vein tumor thrombus treated with TACE combined with portal vein stenting: its clinical significance[J].journal interventional radiology,2015,(08):306.
[7]刘秋松,梅雀林,李彦豪,等.化疗栓塞治疗肝癌合并肝动-静脉分流的生存预后因素分析[J].介入放射学杂志,2015,(12):1056.
 LIU Qiu-song,MEI Que-lin,LI Yan-hao,et al.Interventional chemoembolization for the treatment of hepatocellular carcinoma associated with hepatic arteriovenous shunt: analysis of survival prognostic factors[J].journal interventional radiology,2015,(08):1056.
[8]刘秋松,梅雀林,何晓峰,等.索拉非尼联合PVA微粒化疗栓塞治疗肝癌并肝动-静脉分流的疗效及预后分析[J].介入放射学杂志,2016,(04):320.
 LIU Qiu- song,MEI Que- lin,HE Xiao- feng,et al.Sorafenib plus percutaneous chemoembolization with polyvinyl alcohol for hepatocellular carcinoma complicated by hepatic arteriovenous shunts: analysis of curative effect and prognosis[J].journal interventional radiology,2016,(08):320.
[9]黄 芳,龚环宇,熊正平.雷替曲塞联合奥沙利铂TACE治疗BCLC B/C期肝细胞癌的安全性及疗效[J].介入放射学杂志,2018,27(01):76.
 HUANG Fang,GONG Huanyu,XIONG Zhengping.The safety and efficacy of raltitrexed combined with oxaliplatin in TACE treatment for BCLC B/C hepatocellular carcinomas[J].journal interventional radiology,2018,27(08):76.
[10]戴高乐,罗万权,赵许亚,等.眼部Merkel细胞癌介入治疗1例[J].介入放射学杂志,2020,29(10):1060.
 DAI Gaole,LUO Wanquan,ZHAO Xuya,et al.Successful interventional treatment of Merkel cell carcinoma located at the lateral canthus of left eye: report of one case[J].journal interventional radiology,2020,29(08):1060.
[11]周卫忠,刘 圣,杨正强,等.氰基丙烯酸酯胶栓塞原发性肝细胞癌合并重度肝动脉门静脉瘘12例疗效分析[J].介入放射学杂志,2013,(08):641.
 ZHOU Wei? zhong,LIU Sheng,YANG Zheng? qiang,et al. Transarterial embolization therapy with cyanoacrylate for severe arterioportal shunt associated with hepatocellular carcinoma[J].journal interventional radiology,2013,(08):641.
[12]郑家平,邵国良,罗 君,等. 索拉非尼治疗中晚期肝细胞癌安全性和预后因素分析[J].介入放射学杂志,2014,(03):222.
 ZHENG Jia? ping,SHAO Guo? liang,LUO Jun,et al. Sorafenib for the treatment of intermediate?蛳 advanced hepatocellular carcinomas: its safety and prognostic factors[J].journal interventional radiology,2014,(08):222.
[13]万豪光,许 伟,徐 浩,等. 经导管化疗栓塞联合经皮微波消融治疗中晚期肝癌64例的预后分析[J].介入放射学杂志,2014,(06):477.
 WAN Hao- guang,XU Wei,XU Hao,et al. Transcatheter arterial chemoembolization combined with percutaneous microwave ablation for the treatment of intermediate- advanced hepatocellular carcinoma: analysis of prognostic factors in 64 cases[J].journal interventional radiology,2014,(08):477.
[14]涂文辉,罗剑钧,刘清欣,等.原发性肝癌伴门静脉主干癌栓患者存活超5年1例并文献复习[J].介入放射学杂志,2015,(12):1101.
 TU Wen- hui,LUO Jian- jun,LIU Qing- xin,et al.Primary hepatocellular carcinoma associated with portal vein tumor thrombus: report of one case with survival over 5 years and review of literature [J].journal interventional radiology,2015,(08):1101.
[15]孙 玉,张洪海,生守鹏,等.白蛋白-胆红素分级在早期肝细胞癌射频消融中的预后意义 [J].介入放射学杂志,2021,30(05):502.
 SUN Yu,ZHANG Honghai,SHENG Shoupeng,et al.Prognostic significance of albumin-bilirubin grading in patients with early hepatocellular carcinoma after radiofrequency ablation treatment[J].journal interventional radiology,2021,30(08):502.

备注/Memo

备注/Memo:
(收稿日期:2020- 04- 22)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-08-18